These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 458555)

  • 1. Role of concentration-dependent plasma protein binding in disopyramide disposition.
    Meffin PJ; Robert EW; Winkle RA; Harapat S; Peters FA; Harrison DC
    J Pharmacokinet Biopharm; 1979 Feb; 7(1):29-46. PubMed ID: 458555
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma binding of disopyramide.
    David BM; Madsen BW; Ilett KF
    Br J Clin Pharmacol; 1980 Jun; 9(6):614-8. PubMed ID: 7387819
    [No Abstract]   [Full Text] [Related]  

  • 3. The influence of blood collection technique on serum and plasma protein binding of disopyramide.
    Haughey DB; Lima JJ
    Eur J Clin Pharmacol; 1982; 22(2):185-9. PubMed ID: 7094989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.
    Lima JJ; Boudoulas H; Blanford M
    J Pharmacol Exp Ther; 1981 Dec; 219(3):741-7. PubMed ID: 7299695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative binding of disopyramide phosphate and quinidine sulfate to human plasma proteins.
    Chien YW; Lambert HJ; Karim A
    J Pharm Sci; 1974 Dec; 63(12):1877-9. PubMed ID: 4449018
    [No Abstract]   [Full Text] [Related]  

  • 6. Plasma protein binding of disopyramide by equilibrium dialysis and ultrafiltration.
    David BM; Tjokrosetio R; Ilett KF
    Ther Drug Monit; 1983; 5(1):81-6. PubMed ID: 6845403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein binding and erythrocyte partitioning of disopyramide and its monodealkylated metabolite.
    Hinderling PH; Bres J; Garrett ER
    J Pharm Sci; 1974 Nov; 63(11):1684-90. PubMed ID: 4427225
    [No Abstract]   [Full Text] [Related]  

  • 8. Determination of unbound fraction of disopyramide in plasma: a comparison of equilibrium dialysis, ultrafiltration through dialysis membranes and ultrafree anticonvulsant drug filters.
    Norris RL; Ahokas JT; Ravenscroft PJ
    J Pharmacol Methods; 1982 Jan; 7(1):7-14. PubMed ID: 7070107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma binding of disopyramide and mono-N-dealkyldisopyramide.
    Bredesen JE; Pike E; Lunde PK
    Br J Clin Pharmacol; 1982 Nov; 14(5):673-6. PubMed ID: 7138747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disopyramide plasma concentrations following single and multiple doses of the immediate- and controlled-release capsules.
    Karim A; Schubert EN; Burns TS; Palmer M; Zinny MA
    Angiology; 1983 Jun; 34(6):375-92. PubMed ID: 6346960
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of pKb on lipophilic binding of disopyramide derivatives to human plasma.
    Chien YW; Akers MJ; Yonan PK
    J Pharm Sci; 1975 Oct; 64(10):1632-5. PubMed ID: 241827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies.
    Upton RA; Williams RL
    J Pharmacokinet Biopharm; 1986 Aug; 14(4):365-79. PubMed ID: 3772738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens.
    Ward JW; Kinghorn GR
    J Int Med Res; 1976; 4(1 Suppl):49-53. PubMed ID: 1026529
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical pharmacokinetics of disopyramide.
    Karim A; Nissen C; Azarnoff DL
    J Pharmacokinet Biopharm; 1982 Oct; 10(5):465-94. PubMed ID: 6762414
    [No Abstract]   [Full Text] [Related]  

  • 15. Interaction of disopyramide enantiomers for sites on plasma protein.
    Lima JJ
    Life Sci; 1987 Dec; 41(26):2807-13. PubMed ID: 3695808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Displacement of lidocaine from human plasma proteins by disopyramide.
    Bonde J; Jensen NM; Burgaard P; Angelo HR; Graudal N; Kampmann JP; Pedersen LE
    Pharmacol Toxicol; 1987 Feb; 60(2):151-5. PubMed ID: 3575249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disopyramide plasma levels in cardiac patients on maintenance therapy.
    Landmark K; Storstein L; Larsen A
    Acta Med Scand; 1979; 206(5):385-9. PubMed ID: 525439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.
    Aitio ML
    Br J Clin Pharmacol; 1981 Apr; 11(4):369-75. PubMed ID: 7259930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of intra-individual change in serum protein binding on the pharmacologic response of R- and S-disopyramide in the rabbit.
    Huang JD; Oie S
    Res Commun Chem Pathol Pharmacol; 1983 Aug; 41(2):243-53. PubMed ID: 6635319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disopyramide plasmakinetics and pharmacodynamics applied to the assessment of bioavailability [proceedings].
    Bryson SM; Lawrence JR; Whiting B
    Br J Clin Pharmacol; 1977 Oct; 4(5):633P. PubMed ID: 911618
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.